Dr. Shuguang Huang has 20 years of experience working in pharmaceutical and diagnostic companies. He had assumed technical and management positions at Eli Lilly, Wyeth, Pfizer, and Precision Therapeutics, a cancer diagnostic company. In 2014, he co-founded and assumed the Chief Scientific Officer position for the statistics consulting company Stat4ward LLC.
His expertise includes (i) In-depth real-life expertise in assay development and validation. (ii) biomarker development and exploratory analysis. (iii) CMC and statistical process control.
Dr. Huang is actively involved in guideline development committees of Clinical Laboratory Standard Institute (CLSI) and he is a committee member of American Association of Pharmaceutical Scientists (AAPS) Flow cytometry Action Programming Committee.
Biomarker is very critical in pre-clinical drug discovery, clinical translational research, diagnostic product (including companion diagnostic) development.